Oryzon Genomics - Final update from Phase IIa CLEPSIDRA trial
On 17 September Oryzon presented an update from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, in combination with...
298 Views
Oryzon Genomics - Third positive update from Phase II ALICE trial
Last Friday, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual 25th Congress...
186 Views
Oryzon Genomics - More data support vafidemstat for aggression
On 3 April 2020, Oryzon reported interim data for the first time from its two Phase IIa trials REIMAGINE-AD and ETHERAL. Both explore the company’s...
338 Views
Oryzon Genomics - More to come after a year of data readouts
As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon. The company presented new data from the ongoing Phase IIa...
812 Views
Oryzon Genomics - Maturing ALICE trial dataset continues to impress
On 9 December 2019, Oryzon presented more data from the Phase II ALICE trial at the 61st ASH annual meeting in Orlando, Florida. The single-arm,...
1.8k Views